Korean Circ J.  2018 Oct;48(10):930-932. 10.4070/kcj.2018.0183.

Soluble ST2 in Paroxysmal Atrial Fibrillation: a New Biomarker that Predicts Recurrence?

• AlTurki A

• KMID: 2420645
• DOI: http://doi.org/10.4070/kcj.2018.0183

Abstract

No abstract available.

MeSH Terms

Atrial Fibrillation*
Recurrence*

Reference

1. AlTurki A, Marshall HJ, Proietti R. Targeting nonpulmonary vein triggers during atrial fibrillation ablation: is the game worth the candle? Curr Opin Cardiol. 2018; 33:50–57.

2. Calkins H, Hindricks G, Cappato R, et al. 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation. Heart Rhythm. 2017; 14:e275–e444.

3. Balk EM, Garlitski AC, Alsheikh-Ali AA, Terasawa T, Chung M, Ip S. Predictors of atrial fibrillation recurrence after radiofrequency catheter ablation: a systematic review. J Cardiovasc Electrophysiol. 2010; 21:1208–1216.

4. Tang RB, Yan XL, Dong JZ, et al. Predictors of recurrence after a repeat ablation procedure for paroxysmal atrial fibrillation: role of left atrial enlargement. Europace. 2014; 16:1569–1574.

5. AbouEzzeddine OF, McKie PM, Dunlay SM, et al. Suppression of tumorigenicity 2 in heart failure with preserved ejection fraction. J Am Heart Assoc. 2017; 6:e004382.

6. Aimo A, Vergaro G, Passino C, et al. Prognostic value of soluble suppression of tumorigenicity-2 in chronic heart failure: a meta-analysis. JACC Heart Fail. 2017; 5:280–286.

7. Aimo A, Vergaro G, Ripoli A, et al. Meta-analysis of soluble suppression of tumorigenicity-2 and prognosis in acute heart failure. JACC Heart Fail. 2017; 5:287–296.

8. Eggers KM, Armstrong PW, Califf RM, et al. ST2 and mortality in non-ST-segment elevation acute coronary syndrome. Am Heart J. 2010; 159:788–794.

9. Okar S, Kaypakli O, Şahin DY, Koç M. Fibrosis marker soluble ST2 predicts atrial fibrillation recurrence after cryoballoon catheter ablation of nonvalvular paroxysmal atrial fibrillation. Korean Circ J. 2018; 48:920–929.